Zoetis, a global animal health company released an article titled “The New Science of Cannie Pain”
The article is in regard to the current state of disease with regard to osteoarthritis (OA) in 2 out of every 5 dogs and states that it is believed to be greater than 20% and growing as dogs live longer and obesity is becoming more of an issue.
OA is caused by many factors in both large and small dogs, including developmental issues, injury and obesity. Poor conformation often leads to OA early in life. Conformational changes impact both large (hip dysplasia) and small dogs (patellar luxations).
The article further states… “There is no cure for OA, however, early diagnosis and a multimodal management plan, including pain control, can help keep dogs active, manage weight, and support the quality of life of dogs with OA.”
The article did not take into account PetVivo Holdings, (OTCQB: PETV).
Advances in veterinary health care are providing meaningful improvement in our pets’ lives. There are ongoing innovations in veterinary treatments, preventative medications, diagnostics, screening tools, imaging (MRIs and other scans), wellness products and therapies supported by owners willing to pay for these treatments.
PetVivo, Inc. (OTCQB: PETV), is the producer of “Kush”, which is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis and other lameness issues in dogs and horses that is intended to provide a lubricious cushion within the joint and between the bones to reinforce cartilage. KUSH is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products.
Kush is made from natural materials (collagen elastin and heparin), typically lasts for 12 months or longer and can be repeated annually or as needed.
PetVivo is expected to expand commercial production and availability of Kush in Q1 2021, in the $4.8 billion dog and horse therapeutics market.
PetVivo Holdings, Inc. made a name for itself when a successful Kush case study came to light when Fender Bender, a racehorse suffering from osteoarthritis, was put up for sale and claimed for $3,000.00 and the new owner treated him with PetVivo’s Kush. Fender Bender won at Canterbury Park on August 4, 2020.
As an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals, PetVivo Holdings, Inc. is leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the acceleratedtimeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
Any of the majors in the space could benefit from PetVivo’s proprietary assets, but while PetVivo may or may not be on an acquisition path, it is on an aggressive growth / valuation path. The Company published a press release on December 29, 2020 announcing a reverse stock split in efforts to improve the company’s capital structure related to listing requirements for a planned future listing of the company’s common stock on the Nasdaq Capital Market.
On November 23, 2020, PetVivo Holdings (OTCQB: PETV) filed an 8-K where the Company adopted and approved an amended and restated “Charter of the Audit Committee”, “Charter of the Compensation Committee” and a “Nominating and Corporate Governance Committee Charter?” All of which are required by NASDAQ.
PetVivo has set up the committee’s, conducted the reverse split, and now seems to have all the makings of a NASDAQ stock. See page 11 of the “Nasdaq Official Listing Guide of June 2020”.
Petvivo (OTCQB: PETV) currently has 16 products in its pipeline, and a portfolio of 19 patents that protect them.
Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways. Building on more than 65 years of experience, we deliver quality medicines, vaccines and diagnostic products, complemented by biodevices, genetic tests and precision livestock farming. We are working every day to better understand and address the real-world challenges faced by those who raise and care for animals in ways they find truly relevant.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of eighteen patents protects the Company’s biomaterials, products, production processes and methods of use. The Companys lead product Kush, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.
Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.